Switch theme
Sign up to access all valuation multiples
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
2020
63
LTM Revenue $0.3M
LTM EBITDA -$109M
$236M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ATAI Life Sciences has a last 12-month revenue of $0.3M and a last 12-month EBITDA of -$109M.
In the most recent fiscal year, ATAI Life Sciences achieved revenue of $0.3M and an EBITDA of -$145M.
ATAI Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ATAI Life Sciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.3M | $0.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$36.3M | -$145M | XXX | XXX | XXX |
| EBITDA Margin | -11564% | -47016% | XXX | XXX | XXX |
| Net Profit | -$152M | -$40.2M | XXX | XXX | XXX |
| Net Margin | -48530% | -13060% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ATAI Life Sciences's stock price is $1.
ATAI Life Sciences has current market cap of $274M, and EV of $236M.
See ATAI Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $236M | $274M | XXX | XXX | XXX | XXX | $-0.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ATAI Life Sciences has market cap of $274M and EV of $236M.
ATAI Life Sciences's trades at 810.3x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.
Analysts estimate ATAI Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ATAI Life Sciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $236M | XXX | XXX | XXX |
| EV/Revenue | 766.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | XXX | XXX |
| P/E | -1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpATAI Life Sciences's NTM/LTM revenue growth is -9%
ATAI Life Sciences's revenue per employee for the last fiscal year averaged $5K, while opex per employee averaged $1.6M for the same period.
Over next 12 months, ATAI Life Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ATAI Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ATAI Life Sciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -47016% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 299% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -47025% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $5K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15436% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18005% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 33271% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ATAI Life Sciences acquired XXX companies to date.
Last acquisition by ATAI Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . ATAI Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ATAI Life Sciences founded? | ATAI Life Sciences was founded in 2020. |
| Where is ATAI Life Sciences headquartered? | ATAI Life Sciences is headquartered in United States of America. |
| How many employees does ATAI Life Sciences have? | As of today, ATAI Life Sciences has 63 employees. |
| Who is the CEO of ATAI Life Sciences? | ATAI Life Sciences's CEO is Mr. Srinivas G. Rao, M.D.,PhD. |
| Is ATAI Life Sciences publicy listed? | Yes, ATAI Life Sciences is a public company listed on NAS. |
| What is the stock symbol of ATAI Life Sciences? | ATAI Life Sciences trades under ATAI ticker. |
| When did ATAI Life Sciences go public? | ATAI Life Sciences went public in 2021. |
| Who are competitors of ATAI Life Sciences? | Similar companies to ATAI Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ATAI Life Sciences? | ATAI Life Sciences's current market cap is $274M |
| What is the current revenue of ATAI Life Sciences? | ATAI Life Sciences's last 12-month revenue is $0.3M. |
| What is the current EBITDA of ATAI Life Sciences? | ATAI Life Sciences's last 12-month EBITDA is -$109M. |
| What is the current EV/Revenue multiple of ATAI Life Sciences? | Current revenue multiple of ATAI Life Sciences is 810.3x. |
| What is the current EV/EBITDA multiple of ATAI Life Sciences? | Current EBITDA multiple of ATAI Life Sciences is -2.2x. |
| What is the current revenue growth of ATAI Life Sciences? | ATAI Life Sciences revenue growth between 2023 and 2024 was -2%. |
| Is ATAI Life Sciences profitable? | Yes, ATAI Life Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
